PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.65
+0.09 (+3.52%)
As of 2:25PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.56
Open2.60
Bid2.65 x 1000
Ask2.70 x 800
Day's Range2.60 - 2.83
52 Week Range2.55 - 6.00
Volume14,859
Avg. Volume142,279
Market Cap63.08M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.82
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.67
Trade prices are not sourced from all markets
  • GlobeNewswire7 hours ago

    PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018

    MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire14 days ago

    PhaseBio to Present at Stifel 2018 Healthcare Conference

    MALVERN, Pa. and SAN DIEGO, Nov. 07, 2018 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswirelast month

    PhaseBio Announces Pricing of Initial Public Offering

    PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary, today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million. The shares are expected to begin trading on the Nasdaq Global Market under the symbol “PHAS” on October 18, 2018, and the offering is expected to close on October 22, 2018, subject to customary closing conditions. Citigroup, Cowen and Stifel acted as joint book-running managers for the offering.

  • Benzingalast month

    PhaseBio's IPO: What You Need To Know

    Clinical-stage biopharmaceutical company PhaseBio recently filed for an initial public offering. The stock is expected to trade on the Nasdaq Global Market under the ticker symbol “PHAS.” The Company Founded ...

  • Benzingalast month

    IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, ...